FOSTER CITY, CA, October 29, 2007 – Gilead Sciences, Inc. (Nasdaq: GILD) today announced 48- week data from a Phase III clinical trial evaluating virologically-suppressed patients with HIV who switched from treatment with twice-daily Combivir® lamivudine/zidovudine) to treatment with Gilead’s once-daily Truvada® (emtricitabine and tenofovir disoproxil fumarate) as part of their combination drug ...